|
|
Palisade Bio Inc
PALI's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Palisade Bio Inc 's sales fell
in III. Quarter 2023 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -7.98 %
Palisade Bio Inc net loss decreased from $-4 millions, to $-4 millions in III. Quarter 2023,
• More on PALI's Growth
|
|
Palisade Bio Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.45 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 7.7.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.97.
• More on PALI's Valuation
|
|
|
|
|
Palisade Bio Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 1.45 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 7.7.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.97.
Palisade Bio Inc Price to Book Ratio is at 0.14 lower than Industry Avg. of 1047.61. and higher than S&P 500 Avg. of 0
• More on PALI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
